218 related articles for article (PubMed ID: 15591422)
1. rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H
Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
[TBL] [Abstract][Full Text] [Related]
2. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
4. rHuEPO and treatment outcomes: the clinical experience.
Hudis CA; Van Belle S; Chang J; Muenstedt K
Oncologist; 2004; 9 Suppl 5():55-69. PubMed ID: 15591423
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?
Harrison L; Blackwell K
Oncologist; 2004; 9 Suppl 5():31-40. PubMed ID: 15591420
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.
Mittelman M; Neumann D; Peled A; Kanter P; Haran-Ghera N
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5181-6. PubMed ID: 11309490
[TBL] [Abstract][Full Text] [Related]
7. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation.
Stüben G; Thews O; Pöttgen C; Knühmann K; Sack H; Stuschke M; Vaupel P
Strahlenther Onkol; 2003 Sep; 179(9):620-5. PubMed ID: 14628128
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cancer-related anemia with epoetin alfa: a review.
Ferrario E; Ferrari L; Bidoli P; De Candis D; Del Vecchio M; De Dosso S; Buzzoni R; Bajetta E
Cancer Treat Rev; 2004 Oct; 30(6):563-75. PubMed ID: 15325036
[TBL] [Abstract][Full Text] [Related]
9. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma.
Dammacco F; Luccarelli G; Prete M; Silvestris F
Rev Clin Exp Hematol; 2002; Suppl 1():32-8. PubMed ID: 12735213
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
Prutchi-Sagiv S; Golishevsky N; Oster HS; Katz O; Cohen A; Naparstek E; Neumann D; Mittelman M
Br J Haematol; 2006 Dec; 135(5):660-72. PubMed ID: 17107348
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
Pinel S; Barberi-Heyob M; Cohen-Jonathan E; Merlin JL; Delmas C; Plenat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):250-9. PubMed ID: 15093922
[TBL] [Abstract][Full Text] [Related]
12. Early epoetin alfa treatment in children with solid tumors.
Zoubek A; Kronberger M
Med Pediatr Oncol; 2002 Oct; 39(4):459-62. PubMed ID: 12203664
[TBL] [Abstract][Full Text] [Related]
13. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
15. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin for HIV-related anemia.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):18-24. PubMed ID: 11365957
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Tóvári J; Gilly R; Rásó E; Paku S; Bereczky B; Varga N; Vágó A; Tímár J
Cancer Res; 2005 Aug; 65(16):7186-93. PubMed ID: 16103069
[TBL] [Abstract][Full Text] [Related]
18. Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models.
Boogaerts M; Mittelman M; Vaupel P
Oncology; 2005; 69 Suppl 2():22-30. PubMed ID: 16244507
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
Holley JL; Nolan TA; Piraino B
Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
